Shannon Parisotto Sells 2,039 Shares of Charles River Laboratories International (NYSE:CRL) Stock

Key Points

• Executive vice president Shannon Parisotto sold 2,039 CRL shares for approximately $599,711 under a pre-arranged Rule 10b5-1 trading plan, reducing her ownership by 29.78% to 4,807 shares.
• Charles River Laboratories beat quarterly expectations with $3.02 EPS versus the $2.77 consensus and $1 billion in revenue, although revenue declined 2.7% year over year and the company reported a negative net margin.
• Analysts maintain a generally positive outlook, with a “Moderate Buy” consensus and a $255.65 average price target, while institutional investors own 98.91% of the company.

Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) EVP Shannon Parisotto sold 2,039 shares of the firm's stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $294.12, for a total value of $599,710.68. Following the completion of the transaction, the executive vice president owned 4,807 shares in the company, valued at $1,413,834.84. This represents a 29.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Trading Up 1.0%

NYSE CRL traded up $2.97 on Thursday, reaching $292.97. The company had a trading volume of 1,059,340 shares, compared to its average volume of 927,192. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $299.32. The stock's 50 day moving average is $230.73 and its 200-day moving average is $192.57. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92. The stock has a market cap of $13.99 billion, a price-to-earnings ratio of -60.41, a PEG ratio of 2.89 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.77 by $0.25. The firm had revenue of $1 billion for the quarter, compared to analysts' expectations of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The company's revenue was down 2.7% compared to the same quarter last year. During the same quarter last year, the business earned $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Equities analysts predict that Charles River Laboratories International, Inc. will post 11.35 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CRL has been the topic of a number of recent analyst reports. Piper Sandler set a $300.00 price target on shares of Charles River Laboratories International in a research report on Monday, August 10th. Royal Bank Of Canada lifted their target price on Charles River Laboratories International from $215.00 to $282.00 and gave the stock an "outperform" rating in a report on Thursday, August 6th. BNP Paribas Exane set a $250.00 target price on Charles River Laboratories International in a research note on Wednesday, July 1st. TD Cowen increased their price target on Charles River Laboratories International from $235.00 to $300.00 and gave the stock a "buy" rating in a report on Monday, August 10th. Finally, Citigroup reaffirmed a "buy" rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. Twelve equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $255.65.

Hedge Funds Weigh In On Charles River Laboratories International

A number of large investors have recently added to or reduced their stakes in the company. Invesco Ltd. grew its holdings in shares of Charles River Laboratories International by 115.8% during the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company's stock worth $537,828,000 after buying an additional 1,446,972 shares in the last quarter. Victory Capital Management Inc. lifted its stake in Charles River Laboratories International by 9,938.8% in the 4th quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company's stock valued at $137,935,000 after acquiring an additional 684,586 shares in the last quarter. Ameriprise Financial Inc. boosted its position in Charles River Laboratories International by 1,491.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company's stock worth $96,005,000 after acquiring an additional 575,039 shares during the last quarter. Amundi boosted its position in Charles River Laboratories International by 175.2% during the 1st quarter. Amundi now owns 773,315 shares of the medical research company's stock worth $133,397,000 after acquiring an additional 492,301 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Charles River Laboratories International during the 4th quarter worth approximately $96,765,000. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source